We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER: CONTROVERSY MAIN TRIGGER FOR ADVISORY REVIEW
CDER: CONTROVERSY MAIN TRIGGER FOR ADVISORY REVIEW
January 28, 2004
FDA's Center for Drug Evaluation and Research (CDER) brought its advisory committees together on 44 occasions during 2003 for one- to two-day meetings to cover a wide range of topics including 33 specific drug products; and with the release of its scheduled advisory committee meetings for 2004, the center shows no sign of slowing down, tentatively scheduling more than 40 meetings for the current year (see sidebar).